Lantheus Holdings Inc (FRA:0L8)
€ 72.84 -1.36 (-1.83%) Market Cap: 5.28 Bil Enterprise Value: 5.19 Bil PE Ratio: 12.16 PB Ratio: 5.84 GF Score: 80/100

Lantheus Holdings Inc at UBS Global Healthcare Conference Transcript

May 24, 2022 / 12:30PM GMT
Release Date Price: €58.5 (-4.88%)
John Newton Sourbeer
UBS Investment Bank, Research Division - Equity Research Associate

I'm John Sourbeer, UBS' Life Sciences, Diagnostic Tools and Pharma Services analysts. We're -- our next presentation here, we have Lantheus. We're going to do a little bit of a presentation and then some Q&A.

Starting off, we have President and CEO, Mary Anne Heino. And then we have Robert Marshall, CEO and Treasurer. Mary Anne, would you like to get started?

Mary Anne Heino
Lantheus Holdings, Inc. - CEO, President & Director

Yes. Yes. Good morning, everyone, and thank you for attending. We look forward to talking with you this morning about Lantheus. I'll take a little while to talk to you about our products and what we're trying to achieve with them. And then Bob will bring you up to date on our most recent financials and a look at our strategic goals for the company.

So Mark, if you move forward, as always, I have to offer you our safe harbor statement for any statements we might make today that may be inferred as your right or your privilege

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot